ALZ123 The basics of Alzheimers and other dementia-related - PDF document

1/30/2018 ALZ123 The basics of Alzheimers and other dementia-related illnesses Presented by David Davis STATISTICS A NATIONAL CRISIS Approximately 50,000 in New Mexico Currently there is no treatment, cure or preventive for

  1. 1/30/2018 ALZ123 The basics of Alzheimer’s and other dementia-related illnesses Presented by David Davis STATISTICS A NATIONAL CRISIS • Approximately 50,000 in New Mexico • Currently there is no treatment, cure or preventive for Alzheimer’s. • Over 5 million in the United States • More people die from Alzheimer’s than from breast cancer and • Effects 1 in 8 over the age of 65 prostate cancer combined. • Effects 1 in 2 over the age 0f 85 • When managing care Alzheimer’s and dementia -related • These estimates will likely more than double by 2050 illnesses are the most expensive. RISK FACTORS WHAT IS DEMENTIA? • A condition of global deterioration of memory • The greatest risk factor is age • Genetics and family history and cognition that impairs thought and social • Brain injury functioning. • While there are no preventative measures for Alzheimer’s, Vascular dementia may be prevented by maintaining a healthy lifestyle. 1

  2. 1/30/2018 TYPES OF DEMENTIA WHAT IT IS NOT • It is not a normal part of aging Alzheimer’s Vascular • It is not contagious Lewy Body • It not hereditary Parkinson’s related • Anything intentional on the part of the patient Head trauma or injury All of these types of dementia’s are considered to non -reversible. Some types of dementia, however, are reversible. SYMTOMS DIAGNOSIS • Why is it important? What to look for Can often go un-noticed for years • Why is an early diagnosis even more Who will make observations? important? Say something THE DIAGNOSTIC PROCESS MEDICATIONS • Visit with primary care physician. • Aricept, generic Donezipril • Basic general interview with patient and hopefully a family • Namenda member. • Exelon • Cognitive test. • Basic neurological test. • CT scan or MRI • Spinal tap • Time 2

  3. 1/30/2018 3

  4. 1/30/2018 EXPERIMENTAL DRUG TRIALS IN MULTICENTER VASCULAR DEMENTIA STUDY: BIOMARKERS IN VCID (MARKVCID) ALZHEIMER’S DISEASE AT UNM UNM has been selected as one of 7 Nicotine patch for improvement of memory function. centers around the country to develop A two-year double blind study to test the benefit of nicotine. biomarkers for the diagnosis of vascular cognitive impairment. Patients with cognitive complaints Amyloid antibody to remove amyloid plaques. and/or white matter injury on MRI are The antibody is given by iv infusion each month. recruited for this 5-year study. Improvement in thinking and removal of amyloid are tested. MARKVCID STUDY TESTING GOALS FOR MARKVCID NIH established a 7 center consortium to study the vascular impact on • Biomarkers are collected at entry into the study that can Alzheimer’s disease. be used to predict future diagnoses. • Patients undergo a clinical and neuropsychological In the first two years each center will test examination, a research MRI, and a lumbar puncture for the biomarkers they proposed. CSF. • The goal is to identify patients with inflammation that In the third and fourth years we test have a progressive course. each others biomarkers. • This is the optimal group for treatment trials once a treatment to control inflammation is found. In the fifth year we use the biomarkers to test new treatments. 4

  5. 1/30/2018 UNM MAC Clinical And Research Team RESEARCH COORDINATOR UNM Clinical Group Jillian Prestopnik, PhD • ERIKA PARTRIDGE John Adair, MD • Janice Knoefel, MD • 505-272-7456 • Jeffrey Thompson, BS UNM NMR and MRN EPARTRIDGE@SALUD.UNM.EDU Imaging Group • Arvind Caprihan, PhD • Vince Calhoun, PhD Biostatistician Erik Erhardt • FOR MORE INFORMATION ABOUT: THE MEMORY CARE ALLIANCE THE MEMORY AND AGING CENTER AT UNM ALZHEIMER’S DISEASE DAVID DAVIS DDALZNM@GMAIL.COM 5

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.


More recommend